Regeneron inks big new coronavirus antibody supply deal worth up to $2.6B

Pharma companies worldwide scrambled to respond to the COVID-19 pandemic early last year, but so far only a few have advanced therapies and vaccines through to the market. Regeneron is one, and now the drugmaker's antibody cocktail could bring a multibillion-dollar windfall in 2021. After previously agreeing to supply the U.S. government with 300,000 doses of its antibody cocktail, Regeneron this week inked a much larger supply deal for up to 1.25 million doses. If the company is able to supply all doses, the deal will come out to $2.63 billion. Under the agreement, the government will pay Regeneron for any doses it’s able to produce by the end of June. The government can also purchase any additional doses past that point at its discretion.